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Role of vascular endothelial growth factor in diabetic vascular involved in the pathogenesis of diabetic microvasculopa-
complications thy. This is particularly true with regard to retinal vascu-
Background. Much of the morbidity and mortality associ- lar disease. The recent identification of vascular endothe-ated with diabetes mellitus predominantly reflects its deleteri-
lial growth factor (VEGF) as a primary initiator ofous effects on microcirculation and macrocirculation. During
proliferative diabetic retinopathy, and as a potential me-the past few years, rapid advancement has been made in our
understanding of the mechanisms and molecules involved in diator of nonproliferative retinopathy, has greatly ex-
the pathogenesis of diabetic microvasculopathy. This is particu- panded our molecular understanding of this common,
larly true with regard to retinal vascular disease and the role
sight-threatening disorder. In addition, VEGF has beenof the angiogenesis- and vasopermeability-inducing molecule,
implicated in the development of neuropathy and ne-vascular endothelial growth factor (VEGF).
Methods. Biochemical studies in many relevant cell types phropathy in the patient with diabetes. Conversely, evi-
have been performed. Effects of VEGF action and inhibition dence suggests that VEGF may be beneficial for patients
have been evaluated in animals. Interventions that block the with diabetes and coronary artery or peripheral vascularbiochemical pathways initiated by VEGF have been tested
disease because it may induce the development of car-both in culture and in animals. Human clinical trials have begun.
diac and limb vascular collateralization, respectively.Results. VEGF induces vascular endothelial cell prolifera-
tion, migration and vasopermeability in many cells and tissues. Overall, VEGF appears to play a central role in medi-
In vivo, VEGF has been identified as a primary initiator of ating diabetic vasculopathy in many organs. Improved
proliferative diabetic retinopathy, and as a potential mediator
understanding of the molecular mechanisms underlyingof nonproliferative retinopathy. In addition, VEGF has been
these processes has permitted development of novelimplicated in the development of neuropathy and nephropathy
in the patient with diabetes. In patients with diabetes and therapeutic approaches, several of which are now in hu-
coronary artery or peripheral vascular disease, VEGF may man clinical trials. This paper discusses these advances,
induce development of cardiac and limb vascular collateraliza- identifies some novel therapies in clinical trials, and dis-tion, respectively. Many biochemical processes mediating these
cusses their implications for the future care of vasculopa-actions have now been elucidated.
thy associated with diabetes.Conclusions. VEGF appears to play a central role in medi-
ating diabetic vasculopathy in many organs. Improved un-
derstanding of the molecular mechanisms underlying these
processes has permitted development of novel therapeutic in- VEGF OVERVIEW
terventions, several of which are now in human clinical trials.
VEGF is a highly conserved homodimeric glycopro-These scientific advances and various implications for the fu-
tein composed of four isoforms resulting from alternativeture care of vasculopathy associated with diabetes will be dis-
cussed. mRNA splicing in humans [1]. VEGF is an angiogenic
factor with endothelial cell-selective mitogenic activity
that plays a critically important role in vasculogenesis
Much of the morbidity and mortality associated with [2–5]. VEGF was first recognized as a vasopermeability
diabetes mellitus predominantly reflects its deleterious factor in 1983 [6] and called vasopermeability factor
effects on the microcirculation and macrocirculation. (VPF) due to its very potent permeability-inducing prop-
During the past few years, advancement has been rapid erties that are 50,000 times greater than those of hista-
in our understanding of the mechanisms and molecules mine [7]. VEGF also releases von Willebrand factor and
promotes migration of monocytes [8–10] and vascular
smooth muscle cells [11]. Its expression is increased inKey words: growth factors, angiogenesis, diabetic vascular complica-
tions. many hyperproliferative disorders such as psoriasis [12],
highly vascularized tumors [6, 13–15], leukemia [16], en-Ó 2000 by the International Society of Nephrology
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dometriosis, and various stages of the reproductive pro- cidation of VEGF’s pivotal role in the pathologic angio-
genesis underlying the severe visual loss associated withcess [17–19].
diabetic retinopathy.VEGF mediates its action predominately through two
known VEGF receptors referred to as Flt-1 (VEGFR1)
and Flk-1/KDR (VEGFR2) [20, 21]. Both are transmem- VEGF AND DIABETIC RETINOPATHY
brane autophosphorylating tyrosine kinase proteins of
Loss of retinal capillaries leading to progressive retinal
high VEGF binding affinity. These receptors are ex- hypoxia, increased retinal vascular permeability, and
pressed predominantly in endothelial cells although they new retinal vessel growth are characteristic of diabetic
have been identified in renal mesangial cells, monocytes, retinopathy. Development of new vessels is believed to
hematopoietic cells, and the retina [9, 22–26]. The two be in response to an angiogenic stimulus effected by a
receptors have different signal transduction properties diffusable growth factor produced within the eye. The
[27, 28] and induced phosphorylation of at least 11 pro- concept of a soluble diffusable “factor X” was first pro-
teins in bovine aorta endothelial cells, including phos- posed by Michaelson more than half a century ago [40],
pholipase C g (PLCg), phosphotidylinositol 3-kinase, and numerous angiogenic growth factors have since been
ras guanine 59 triphosphate (GTP)ase-activating protein, identified in eyes with diabetic retinopathy. These in-
and several others [29]. Published evidence suggests that clude insulin-like growth factors (IGF) [43], basic fibro-
nitric oxide mediates some of VEGF’s mitogenic effect blast growth factor (bFGF) [44], hepatocyte growth fac-
on coronary endothelial cells [30]. The induced tyrosine tor (HGF) [45], and VEGF [46]. To date, only VEGF has
phosphorylation of PLCg may be of importance in dia- been shown to possess all those properties presumably
betic retinopathy in that activated PLCg converts inositol required for a major mediator of proliferative diabetic
phosphates to diacylglycerol, inducing activation and retinopathy.
translocation of protein kinase C (PKC) a, b and d iso- Expression of VEGF mRNA in ocular cell cultures is
forms, and subsequent increases in mitogenesis and per- inducible by hypoxia and reversed by reinstitution of
meability of retinal endothelial cells [31]. normoxia [47]. Many cells in the eye can produce VEGF,
VEGF and its receptors have diverse and distinct roles including retinal pigment epithelium, endothelial cells,
pericytes, glial cells, and ganglion cells [47, 48]. Retinalin physiologic angiogenesis but are also essential for nor-
endothelial cells possess many VEGF receptors [49] andmal embryogenesis. Loss of a single VEGF allele results
VEGF is capable of stimulating retinal endothelial cellin early embryonic death [32, 33]. Although the presence
proliferation in vitro. Several animal models of hypoxia-of both receptor types are required for normal em-
induced ocular neovascularization have been studied tobryogenesis, Flk-1/KDR is important for regulation of
investigate the potential role of VEGF. Neonatal ani-hematopoiesis and vasculogenesis, whereas Flt-1 recep-
mals, including mice [50], rats [51], and cats [52], fail totors are involved in organization of normal vascular
fully develop their retinal vasculature when exposed tochannels [32, 33]. In early postnatal mice, VEGF inhibi-
supranormal oxygen concentrations. When these ani-tion results in abnormal development of renal glomeruli,
mals were returned to normal room oxygen concentra-kidney failure, impaired liver development [34], abnor-
tions, a state of relative hypoxia occurs in the retinamal trabecular bone formation [35], and absence of cor-
and intraocular neovascularization develops. Elevatedpus luteum [36].
VEGF mRNA and retinal VEGF proteins were demon-VEGF mRNA expression is dramatically regulated by
strated in the ischemic retina and in the retina just ante-oxygen tension, with markedly increased VEGF gene
rior to the areas of retinal neovascularization [53]. Simi-expression under hypoxic conditions [37]. The mecha-
lar findings of elevated VEGF were found in eyes of
nisms regulating the hypoxic induction of VEGF expres- nonhuman primates with retinal ischemia secondary to
sion are similar to those of erythropoietin and involve a iatrogenic central retinal vein occlusion [54]. A temporal
homologous gene sequence closely related to a hypoxia- association between the concentration of intraocular
inducible factor-1 binding domain [38, 39]. VEGF and the development and subsequent regression
These properties of VEGF suggested that it might regu- of iris neovascularization was also observed.
late the neovascularization common to hypoxia-induced More conclusive evidence indicating the causal rela-
disorders such diabetic retinopathy [40, 41]. Indeed, dia- tionship between VEGF and hypoxia-induced neovascu-
betic retinopathy (which is characterized in its advanced larization was obtained by specific inhibition of VEGF
stages by proliferating retinal vessels and marked in- in these animal models. In mice, soluble VEGF receptor
creases in vasopermeability) remains a major worldwide chimeric proteins, which bind free VEGF and prevent
problem and persists as the leading cause of new onset its binding to cellular receptors, reduced neovasculariza-
blindness among working age Americans. In 1993, retinal tion in 95% to 100% of animals tested with a mean of
pigment cells were shown to produce VEGF by Northern 50% [55]. Antisense oligonucleotides in mice [56] and
blot analysis, in situ hybridization, and immunoassay VEGF-neutralizing antibodies in monkeys [57] also de-
creased ocular neovascularization.techniques [42]. Subsequent investigations led to the elu-
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Clinical studies have confirmed the correlation be- hypoxic retina, and stimulates neovascularization both
locally and at a distance [40, 41]. Furthermore, compel-tween ischemic retinopathies and intraocular VEGF con-
centrations [46, 58]. Elevated VEGF concentrations ling evidence indicates that VEGF alone is sufficient to
produce the changes characteristic of advanced retinopa-were demonstrated in vitreous and aqueous samples of
143 eyes in patients with proliferative retinopathies who thy and possibly of earlier retinopathy as well, including
microaneurysms, vascular loss, vascular caliber abnor-were undergoing intraocular surgery [46]. Elevated
VEGF levels were obtained in the presence of active malities, increased vascular permeability, changes in reti-
nal blood flow, and new vessel formation both in theintraocular neovascularization irrespective of the under-
lying cause of the retinopathy, which included diabetic retina and in the iris. Inhibition of VEGF suppresses
retinal neovascularization and increased retinal vascularretinopathy, central retinal vein occlusion, and retinopa-
thy of prematurity. In contrast, VEGF concentrations permeability, which suggests that agents that block VEGF
action might provide novel therapeutic approaches towere low in eyes with non-neovascular disorders and in
samples from patients with diabetes without retinopathy diabetic vasculopathy. However, the suppression of neo-
vascularization is often not total, suggesting that growthor with regressed (inactive) proliferative retinopathy. In
six patients who had ocular fluid obtained both before factors other than VEGF may play a role as well.
and after successful laser therapy, intraocular VEGF
concentration was reduced by a mean of 75%. Moreover,
VEGF AND DIABETIC NEPHROPATHY
vitreous samples from patients with active proliferative
The precise role of VEGF in diabetic nephropathy isretinopathy stimulated endothelial cell growth in vitro
uncertain. However, growth factors are believed to be ofand this was correlated with the extent of VEGF in the
importance in the development of diabetic renal disease.samples. Finally, in eyes in which both the vitreous and
Unlike other forms of nephropathies that are associatedaqueous fluids were available for analysis, the concentra-
with renal tissue destruction and atrophy, diabetic ne-tion of VEGF in the vitreous was consistently higher
phropathy can be associated with glomerular tissue hyper-that that found in the aqueous.
trophy, proximal tubular hypertrophy, mesangial matrixA characteristic of ocular neovascularization is in-
expansion, and ultimately glomerulosclerosis [63, 64]. In-creased vascular permeability. Many patients with diabe-
deed, overexpression of several growth factors has beentes, especially those with type 2 diabetes mellitus, suffer
demonstrated in experimental diabetic nephropathy, in-moderate visual impairment secondary to macula edema
cluding platelet-derived growth factor (PDGF), bFGF,as a consequence of leakage from retinal vessels. This can
and transforming growth factor-b (TGF-b) [65]. TGF-boccur with or without retinal neovascularization. The vaso-
has been investigated extensively in diabetic nephropa-permeability effect of VEGF could theoretically account
thy both in experimental models and in patients. Thisfor these changes. In retinas of diabetic rats, hyperper-
cytokine may account for some changes observed in dia-meability, as determined by immunohistologic detection
betic nephropathy including increased up-regulation ofof extravasated albumin, was associated with increased
collagen synthesis and enhanced extracellular matrixVEGF immunoreactivity [59]. Moreover, intraocular in-
(ECM) component accumulation [63].jections of VEGF at concentrations observed clinically
Inasmuch as some pathologic processes, such as endo-during diabetic retinopathy resulted in rapid, dose-
thelial dysfunction, loss of smooth muscle cells, forma-dependent increases in retinal vascular permeability as
tion of microaneurysms, and increased blood vessel per-assessed by vitreous fluorophotometry [60].
meability, are observed in both diabetic retinopathy andIn the nonhuman primate eye, repeated intraocular
diabetic nephropathy [66, 67], the role of VEGF in theinjections of VEGF produced vascular tortuosity, capil-
development of diabetic nephropathy has recently beenlary abnormalities resembling microaneurysms, flame hem-
explored. Evidence suggests that in the diabetic milieu,orrhages, capillary closure, and fluorescein leakage dur-
VEGF expression by glomerular endothelial, tubular,ing angiography [61]. These retinal changes resemble the
and mesangial cells can be up-regulated by hypoxia, highclinical picture of nonproliferative diabetic retinopathy.
glucose-induced protein kinase C (PKC) activation, orClinically, patients with diabetes have a 33% decrease in
TGF-b–mediated pathways [63]. In addition, early andretinal blood flow early in the course of retinopathy with
transient increases in VEGFR2 receptors occur in dia-retinal blood flow increasing progressively in more ad-
betic rat models [68]. However, the role of VEGF andvanced stages of retinopathy [62]. Similar changes in reti-
its receptors in diabetic nephropathy remains to be delin-nal blood flow are observed in diabetic rats. Intravitreal
eated fully because certain VEGF isoforms appear toinjections of VEGF in diabetic rats demonstrated that
mediate glomerular endothelial repair in some formsVEGF increased retinal blood flow and that diabetic rats
of nondiabetic renal pathology [69]. In a rat model ofwere more sensitive to this effect than nondiabetic rats.
nephritis, inhibition of VEGF 165 using VEGF aptamersOverall, VEGF fits the Michaelson hypothesis of a
soluble factor that is freely diffusable, produced in the suggested that VEGF 165 is essential for glomerular cell
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repair. Furthermore, in this model, treatment with VEGF dependent mechanism [31] as is VEGF-induced retinal
permeability [60]. These processes are inhibited by PKCaptamer did not affect mesangial cell proliferation, accu-
inhibitors. Further investigations have revealed thatmulation of ECM, or proteinuria. Therefore, it is cur-
VEGF-induced endothelial cell mitogenesis and perme-rently uncertain whether expression of VEGF is, at least
ability are predominantly mediated by the b-isoform ofin part, the cause of the pathologic changes in nephropa-
PKC. Currently, an orally administered, PKC b-selectivethy or rather represents a reparative response as a conse-
inhibitor (LY333531) is being evaluated in multinational,quence of preexisting tissue and functional alterations.
randomized, placebo-controlled clinical trials to assess
its potential to prevent, delay, or ameliorate proliferative
VEGF AND DIABETIC diabetic retinopathy and diabetic macula edema [80]. In
MACROVASCULOPATHY addition, several VEGF inhibitors that are initially being
Cardiovascular disease remains a major concern in evaluated for their effectiveness against VEGF-medi-
patients with diabetes. The risk of cardiovascular disease ated neoplasms would be of potential therapeutic use-
in such patients is two to five times that of control pa- fulness against diabetic ocular complications. These ap-
tients [70, 71]. In the United States, the age-adjusted proaches that are currently in or approaching clinical
prevalence for ischemic heart disease, stroke, and pe- trials include neutralizing humanized antibodies, aptam-
ripheral vascular disease in patients with diabetes is 30% ers, small molecule VEGF receptor inhibitors, antisense
to 51%, 10%, and 9%, respectively [72]. Previous silent oligonucleotides, and endogenous inhibitors such as en-
myocardial infarction (MI) is present in 40% of patients dostatin, angiostatin, pigment epithelial-derived factor,
with diabetes who present with their first symptomatic and several others.
MI [73]. The patient with diabetes and MI has a twofold In addition to evaluating the effectiveness of these
increase in mortality in the first month post-MI as com- novel anti-VEGF approaches, several significant issues
pared with nondiabetic patients [74]. regarding anti-VEGF therapy remain unresolved. For
Although not currently directly implicated in the de- example, although a low level of VEGF is produced in
velopment of diabetes-related atherosclerotic disease, many tissues under normal conditions [22], it is not
VEGF may serve a salutary role in the hypoxic myocar- known whether this basal amount of VEGF expression
dial tissues of coronary artery disease by promoting de- is necessary for normal function of the adult eye or other
velopment of collateral circulation. The beneficial effects organs. The effects of systemically administered anti-
VEGF therapies could be associated with undesirableof collateral coronary blood vessels during MI have been
side effects related to certain physiologic responses indocumented [75]. It is possible that VEGF may be pro-
adults that require appropriate angiogenesis, such asduced in response to tissue hypoxemia secondary to grad-
wound healing, vascular collateralization, the reproduc-ual occlusion of coronary vessels. Indeed, the normal
tive cycle, and embryonic development. In addition, ithuman myocardium expresses VEGF mRNA [76] and
remains unknown whether these approaches may re-myocardial mRNA expression is up-regulated by hyp-
quire lifelong therapy. Finally, appropriate drug deliveryoxia in some cultured cardiac cell systems [77]. VEGF
methods will need to be evaluated to ensure adequatelevels are also elevated in the serum of patients following
concentration of anti-VEGF at the target organ. Obvi-acute MI [78]. However, great interindividual variability
ously, repeated intraocular injections with their potentialexists in the extent of collateral formation in patients
for considerable associated ocular morbidity would notwith coronary vessel disease [79], possibly related to
be an optimal delivery technique for such a chronic dis-reduced VEGF induction by hypoxia.
ease as diabetes.
In contrast to the anti-VEGF therapeutic strategy em-
NOVEL THERAPEUTIC APPROACHES TO ployed to treat diabetic retinopathy, VEGF augmentation
DIABETIC VASCULAR COMPLICATIONS might be expected to be beneficial in promoting collateral
Understanding the role played by VEGF in diabetic vascularization for the treatment of peripheral vascular
vascular complications and elucidating the molecular or cardiac disease. Such “therapeutic angiogenesis” has
mechanisms underlying these actions has opened a new been studied in animals and humans. Enhanced collateral
therapeutic frontier for strategies aimed at lessening the formation developed in porcine models of chronic myo-
morbidity associated with microvascular and macrovas- cardial ischemia after the myocardium was injected with
cular disease. In diabetic retinopathy, excessive intraocu- VEGF protein, adenoviral VEGF expression vectors, or
lar neovascularization and increased retinal vascular per- direct intramyocardial transfection with naked cDNA en-
meability are major causes of visual loss. Because it is coding VEGF [81, 82]. Early clinical studies involving
thought that VEGF plays a central role in mediating VEGF cDNA myocardial gene transfer in patients with
these complications, inhibition of VEGF activity could symptomatic myocardial ischemia who had failed conven-
be clinically useful. Studies have demonstrated that VEGF- tional therapy showed significant symptomatic improve-
ment and reduced nitroglycerin usage [83].induced endothelial cell growth is mediated by a PKC-
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Similarly, studies have evaluated peripheral vascular may facilitate development of potential therapeutic strat-
egies to prevent or retard the progression of diabeticdisease. Collateral circulation was improved with VEGF
treatment in skeletal muscles of diabetic animals with renal disease. In contrast, recognition of the potential
beneficial role of VEGF augmentation for inducing com-hind-limb ischemia [84]. Isner and associates have dem-
onstrated increased collateral vessel formation in the pensatory vascular collateralization in the ischemic myo-
cardium or peripheral limb holds the potential to amelio-limb of a patient with severe limb ischemic after VEGF165
gene transfer administered during angioplasty [85]. An- rate the morbidity of diabetic macrovasculopathy. The
first few years of this new century should prove an excit-other study evaluated therapeutic angiogenesis using
naked cDNA encoding VEGF that was injected into ing period for understanding the clinical effectiveness of
these novel therapeutic approaches as a series of clinicalmuscles of 10 patients who were awaiting amputation
procedures with ischemic limb rest pain and nonhealing trial results are released. If the therapeutic modulation
of growth factors proves efficacious, it might herald theulcers. Significant improvement in symptoms, ulcer heal-
ing, and limb salvage rate was observed [86]. onset of new paradigms in the management of diabetic
vascular complications.From these discussions, it is clear that opposing para-
digms for the potential therapeutic modulation of angio-
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